Barclays analyst Luke Sergott raised the firm’s price target on Twist Bioscience to $30 from $26 and keeps an Overweight rating on the shares. In a research note on Friday, the firm argued that a solid quarter and conservative guide leave room for upside from Express Genes contributing to the business. Barclays is already starting to see gross margins improving due to FoF and expects Express Genes will only accelerate the gross margin ramp over the next couple of years.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TWST:
- Twist Bioscience price target raised to $32 from $26 at Evercore ISI
- Twist Bioscience sees FY24 revenue $285M-$290M, consensus $298.67M
- Twist Bioscience sees Q1 revenue $67M-$68M, consensus $63.45M
- Twist Bioscience reports Q4 EPS (81c), consensus (92c)
- Options Volatility and Implied Earnings Moves Today, November 17, 2023
